Search results for " Real-world"

showing 10 items of 25 documents

Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience

2019

Data from 423 human epidermal growth factor receptor 2-negative (HER2−), hormone receptor-positive (HR+) advanced breast cancer (aBC) patients treated with palbociclib and endocrine therapy (ET) were provided by 35 Italian cancer centers and analyzed for treatment outcomes. Overall, 158 patients were treated in first line and 265 in second/later lines. We observed 19 complete responses and 112 partial responses. The overall response rate (ORR) was 31% (95% confidence interval [CI], 26.6–35.4) and clinical benefit was 52.7% (95% CI, 48–57.5). ORR was negatively affected by prior exposure to everolimus/exemestane (p = 0.002) and favorably influenced by early line-treatment (p < 0.0001). At…

Male0301 basic medicineOncologyPyridinesReceptor ErbB-2PhysiologyClinical BiochemistryPiperazineschemistry.chemical_compound0302 clinical medicineExemestaneAntineoplastic Combined Chemotherapy Protocolsadvanced breast cancer; hormonal therapy; endocrine resistance; palbociclib; real-world settingBreastAged 80 and overadvanced breast cancerhormonal therapyadvanced breast cancer hormonal therapy; endocrine resistance; palbociclib; real-world settingMiddle AgedTreatment OutcomeReceptors Estrogen030220 oncology & carcinogenesisToxicityFemaleReceptors Progesteronemedicine.drugAdultadvanced breast cancer hormonal therapy; endocrine resistance; palbociclib; real-world setting; Physiology; Clinical Biochemistry; Cell Biologymedicine.medical_specialtypalbociclibBreast NeoplasmsPalbociclibNeutropeniaadvanced breast cancer hormonal therapyDisease-Free Survivalendocrine resistance03 medical and health sciencesInternal medicinereal-world settingmedicineHumansAgedEverolimusSettore MED/06 - ONCOLOGIA MEDICAbusiness.industryCancerCell Biologymedicine.diseaseConfidence interval030104 developmental biologychemistryMED/06 - ONCOLOGIA MEDICAbusinessHormone
researchProduct

Circadian rhythm of COPD symptoms in clinically based phenotypes. Results from the STORICO Italian observational study

2019

Abstract Background Chronic Obstructive Pulmonary Disease (COPD) encompasses various phenotypes that severely limit the applicability of precision respiratory medicine. The present investigation is aimed to assess the circadian rhythm of symptoms in pre-defined clinical COPD phenotypes and its association with health-related quality of life (HR-QoL), the quality of sleep and the level of depression/anxiety in each clinical phenotype. Methods The STORICO (NCT03105999) Italian observational prospective cohort study enrolled COPD subjects. A clinical diagnosis of either chronic bronchitis (CB), emphysema (EM) or mixed COPD-asthma (MCA) phenotype was made by clinicians at enrollment. Baseline e…

MaleChronic bronchitisTime FactorsHealth StatusAnxietyHospital Anxiety and Depression ScaleSeverity of Illness IndexHealth StatuPulmonary Disease Chronic Obstructive0302 clinical medicineSurveys and QuestionnairesForced Expiratory VolumeClinical phenotypeMedicineSurveys and QuestionnaireRespiratory function030212 general & internal medicineProspective StudiesProspective cohort studyLungDepression (differential diagnoses)COPDDepressionMiddle AgedCircadian RhythmPhenotypeItalyAnxietyFemalemedicine.symptom24-hour symptoms Clinical phenotype Real-world Respiratory functionResearch ArticleHumanPulmonary and Respiratory Medicinemedicine.medical_specialtyChronic ObstructiveTime FactorSettore MED/10 - Malattie Dell'Apparato RespiratorioPulmonary Disease03 medical and health sciencesInternal medicineHumansAsthma24-hour symptoms; Clinical phenotype; Real-world; Respiratory function; Aged; Anxiety; Depression; Female; Forced Expiratory Volume; Health Status; Humans; Italy; Lung; Male; Middle Aged; Phenotype; Prospective Studies; Pulmonary Disease Chronic Obstructive; Severity of Illness Index; Sleep; Surveys and Questionnaires; Time Factors; Circadian Rhythm; Quality of LifeAgedlcsh:RC705-77924-hour symptomsbusiness.industryCorrectionlcsh:Diseases of the respiratory systemmedicine.disease24-hour symptomProspective Studie030228 respiratory systemReal-worldQuality of LifebusinessSleepRespiratory function
researchProduct

Injectable Versus Oral First-Line Disease-Modifying Therapies: Results from the Italian MS Register

2021

AbstractThe current study aims to compare injectable and oral first-line disease-modifying therapies (DMTs) for time to first relapse, time to confirmed disability progression (CDP), and time to discontinuation using a cohort of relapsing remitting multiple sclerosis (RRMS) patients, with data extracted from the Italian MS Register. This multicenter, observational, retrospectively acquired, and propensity-adjusted cohort study utilized RRMS-naïve patients from the Italian MS Register who started either injectable or oral first-line DMTs between January 1, 2010, and December 31, 2017, to evaluate the impact on disability outcomes in patients. Enrolled patients were divided into two groups, n…

Maleoral DMTsoral DMTAdministration OralDiseaseRelapsing-RemittingCohort Studies0302 clinical medicineImmunologicinjectable DMTPharmacology (medical)030212 general & internal medicineRegistriesSubcutaneousMiddle AgedItalyEDSS score; injectable DMTs; Multiple sclerosis; oral DMTs; real-world setting; Adjuvants Immunologic; Administration Oral; Adult; Cohort Studies; Female; Follow-Up Studies; Glatiramer Acetate; Humans; Immunologic Factors; Injections Subcutaneous; Interferon-beta; Italy; Male; Middle Aged; Multiple Sclerosis Relapsing-Remitting; Retrospective Studies; RegistriesAdministrationCohortSettore MED/26 - NeurologiaOriginal ArticleFemaleNeurosurgeryCohort studyOralAdultmedicine.medical_specialtyEDSS scoreInjections SubcutaneousLower riskInjectionsMultiple sclerosis03 medical and health sciencesMultiple Sclerosis Relapsing-RemittingAdjuvants ImmunologicInternal medicinereal-world settingmedicineHumansImmunologic FactorsMultiple sclerosiAdjuvantsinjectable DMTsRetrospective StudiesPharmacologybusiness.industryMultiple sclerosisGlatiramer AcetateInterferon-betamedicine.diseaseDiscontinuationObservational studyNeurology (clinical)business030217 neurology & neurosurgeryFollow-Up Studies
researchProduct

Do patients' and referral centers' characteristics influence multiple sclerosis phenotypes? Results from the Italian multiple sclerosis and related d…

2022

Abstract Background Multiple sclerosis (MS) is characterized by phenotypical heterogeneity, partly resulting from demographic and environmental risk factors. Socio-economic factors and the characteristics of local MS facilities might also play a part. Methods This study included patients with a confirmed MS diagnosis enrolled in the Italian MS and Related Disorders Register in 2000–2021. Patients at first visit were classified as having a clinically isolated syndrome (CIS), relapsing–remitting (RR), primary progressive (PP), progressive-relapsing (PR), or secondary progressive MS (SP). Demographic and clinical characteristics were analyzed, with centers’ characteristics, geographic macro-ar…

Multiple SclerosisCenters’ characteristics; Italian Multiple Sclerosis Register; Multiple sclerosis phenotypes; Real-world dataSettore MED/42 - Igiene Generale e ApplicataItalian Multiple Sclerosis RegisterDermatologyGeneral MedicineMultiple Sclerosis Chronic ProgressiveSettore MED/26Settore SECS-S/04 - DemografiaCenters’ characteristicsMultiple sclerosis phenotypeReal-world dataSettore MED/01 - Statistica MedicaPsychiatry and Mental healthMultiple Sclerosis Relapsing-RemittingPhenotypeRecurrenceHumansFemaleSettore MED/26 - NeurologiaNeurology (clinical)Centers’ characteristicReferral and ConsultationMultiple sclerosis phenotypes
researchProduct

Evolving patterns of care and outcomes in relapsed/refractory FLT3 mutated acute myeloid leukemia adult patients.

2021

We have analyzed treatment patterns and outcomes of relapsed/refractory(R/R) FLT3mut AML adult patients registered in our institutional data base between 1998 and 2018. Overall, 147 patients were evaluable: 34 from 1998 to 2009, 113 from 2010 to 2018. Salvage treatments were intensive chemotherapy ( n = 25, 74%), and supportive care ( n = 9, 26%) in the 1998-2009 period, and intensive chemotherapy ( n = 63, 56%), hypomethylating agent ( n = 7, 6%), low-dose cytarabine-based ( n = 8, 7%), clinical trial ( n = 16, 14%) and supportive care ( n = 19, 17%) in the 2010-2018 period. Complete remission (CR) or with incomplete recovery (CRi) rate was 44%, 49% among patients treated intensively (vs 3…

OncologyAdultCancer Researchmedicine.medical_specialtyreal-world*real-world03 medical and health sciences0302 clinical medicineRefractoryInternal medicineAntineoplastic Combined Chemotherapy Protocolsmedicine*FLT3mut AMLHumansPatterns of carerelapseSalvage TherapyAdult patientsFLT3mut AMLbusiness.industryFLT3mut AML real-world relapse/refractoryRemission InductionCytarabineMyeloid leukemiaHematology*relapse/refractoryrefractoryLeukemia Myeloid AcuteTreatment OutcomeOncologyfms-Like Tyrosine Kinase 3030220 oncology & carcinogenesisRelapsed refractorybusiness030215 immunologyLeukemialymphoma
researchProduct

A real-world economic analysis of biologic therapies for moderate-to-severe plaque psoriasis in Italy: results of the CANOVA observational longitudin…

2021

AbstractBackgroundPsoriasis is a chronic immune-mediated inflammatory skin disease which can also involve joints. It is often associated with burdensome comorbidities which negatively impact prognosis and quality of life (QoL). Biologic agents have been shown to be effective in controlling disease progression, but their use is associated with higher costs compared with traditional systemic treatments. The economic analysis of the CANOVA (EffeCtiveness of biologic treAtmeNts for plaque psOriasis in Italy: an obserVAtional longitudinal study of real-life clinical practice) study aims to assess the costs and cost-effectiveness of biologics in a real-world context in Italy.MethodsThe annualised…

Response ratemedicine.medical_specialtyCost per responderBiologicCostIxekizumabLongitudinal StudieContext (language use)Secukinumab.Severity of Illness IndexAntibodiesIndirect costsSettore MED/35Quality of lifeInternal medicinePsoriasisUstekinumabMonoclonalAdalimumab; Ixekizumab; Antibodies Monoclonal; Longitudinal Studies; Quality of Life; Psoriasis; Treatment Outcome; Severity of Illness Index; Italy; Humans; Biological Therapy; Ustekinumab; Secukinumab; Response rate; Real-world; Ixekizumab; Cost per responder; BiologicmedicineAdalimumabHumansPsoriasisLongitudinal Studieshealth care economics and organizationsSecukinumabPsoriasiAdalimumab; Biologic; Cost per responder; Costs; Ixekizumab; Real-world; Response rate; Secukinumab; Ustekinumab; Antibodies Monoclonal; Biological Therapy; Humans; Italy; Longitudinal Studies; Severity of Illness Index; Treatment Outcome; Psoriasis; Quality of Lifebusiness.industryHealth PolicyResearchAdalimumabAntibodies Monoclonalmedicine.diseaseCostsBiological TherapyIxekizumabTreatment OutcomeReal-worldItalyQuality of LifeSecukinumabUstekinumabPublic aspects of medicineRA1-1270Settore MED/35 - MALATTIE CUTANEE E VENEREEbusinessHumanmedicine.drugBMC Health Services Research
researchProduct

An evaluation of recent local image descriptors for real-world applications of image matching

2019

This paper discusses and compares the best and most recent local descriptors, evaluating them on increasingly complex image matching tasks, encompassing planar and non-planar scenarios under severe viewpoint changes. This evaluation, aimed at assessing descriptor suitability for real-world applications, leverages the concept of approximated overlap error as a means to naturally extend to non-planar scenes the standard metric used for planar scenes. According to the evaluation results, most descriptors exhibit a gradual performance degradation in the transition from planar to non-planar scenes. The best descriptors are those capable of capturing well not only the local image context, but als…

Settore ING-INF/05 - Sistemi Di Elaborazione Delle InformazioniSettore INF/01 - InformaticaImage matchingComputer sciencebusiness.industryVisual descriptorsComputingMethodologies_IMAGEPROCESSINGANDCOMPUTERVISIONPattern recognition02 engineering and technology03 medical and health sciences0302 clinical medicineLocal Image Descriptors; Image MatchingRobustness (computer science)Computer Science::Computer Vision and Pattern RecognitionComputer Science::Multimedia030221 ophthalmology & optometry0202 electrical engineering electronic engineering information engineering020201 artificial intelligence & image processingArtificial intelligencebusinessImage matching Data-driven approach Descriptors Evaluation results Local descriptors Local image descriptors Performance degradation Real-worldScene structure Computer vision
researchProduct

Treatment of Hepatocellular Carcinoma with Immune Checkpoint Inhibitors and Applicability of First-Line Atezolizumab/Bevacizumab in a Real-Life Setti…

2021

Immune checkpoint inhibitors (ICIs) are the new frontier for the treatment of advanced hepatocellular carcinoma (HCC). Since the first trial with tremelimumab, a cytotoxic T-lymphocyte-associated protein 4 inhibitor, increasing evidence has confirmed that these drugs can significantly extend the survival of patients with advanced hepatocellular carcinoma (HCC). As a matter of fact, the overall survival and objective response rates reported in patients with advanced HCC treated with ICIs are the highest ever reported in the second-line setting and, most recently, the combination of the anti-programmed death ligand protein-1 atezolizumab with bevacizumab—an anti-vascular endothelial growth fa…

SorafenibOncologymedicine.medical_specialtyBevacizumabPopulationSystemic treatmentReviewunresectable hepatocellular carcinoma03 medical and health sciences0302 clinical medicineAtezolizumabInternal medicinemedicineeducationSettore MED/12 - Gastroenterologiaeducation.field_of_studybusiness.industryRGeneral Medicinemedicine.diseaseUnresectable hepatocel-lular carcinomaRegimenReal-world030220 oncology & carcinogenesisHepatocellular carcinomaMedicine030211 gastroenterology & hepatologyImmunotherapybusinessLiver cancerImmunotherapy; Liver cancer; Real-world; Systemic treatment; Unresectable hepatocel-lular carcinomaLiver cancerTremelimumabmedicine.drugJournal of Clinical Medicine
researchProduct

Adherence to omalizumab: A multicenter “real-world” study

2020

Background: Adherence to medications is crucial in patients with severe asthma in light of the negative clinical impact and costs of non-adherence. Adherence to omalizumab has not been well studied in real-world settings. The aim of this study was to assess adherence to omalizumab and evaluate treatment effectiveness in relation to adherence. Methods: This was a retrospective, observational, and multicenter real-world study. Omalizumab dose, timing of administration, and duration of treatment ( 4 years) were analyzed. Adherence was evaluated by examining rates of expected and missing doses. Good adherence (10% doses missed) were determined. For effectiveness in relation to adherence of omal…

lcsh:Immunologic diseases. AllergyPulmonary and Respiratory Medicinemedicine.medical_specialtySevere asthmaEfficacySevere asthmaImmunologyOmalizumabOmalizumabSettore MED/10 - Malattie Dell'Apparato RespiratorioArticlePoor adherence03 medical and health sciences0302 clinical medicineInternal medicineImmunology and AllergyMedicineIn patient030223 otorhinolaryngologyAsthmaAsthma exacerbationsbusiness.industrySevere asthma Omalizumab Adherence Efficacy Real-worldmedicine.disease030228 respiratory systemReal-worldAdherenceObservational studylcsh:RC581-607businessAsthma Control Testmedicine.drug
researchProduct

Kidney Disease Management in the Hospital Setting: A Focus on Inappropriate Drug Prescriptions in Older Patients

2021

Aging with multimorbidity and polytherapy are the most significant factors that could led to inappropriate prescribing of contraindicated medications in patients with chronic kidney disease (CKD). The aim of this study was to evaluate the prescriptions of contraindicated drugs in older adults in CKD and to identify their associated factors in a hospital context. An observational retrospective study was carried out considering all patients ≥65 years with at least one serum creatinine value recorded into the REPOSI register into 2010–2016 period. The estimated glomerular filtration rate (eGFR) was applied to identify CKD. A descriptive analysis was performed to compare demographic and clinica…

medicine.medical_specialtyappropriateness of prescriptionprescribing patternsRenal functionContext (language use)RM1-950Logistic regressionNOchemistry.chemical_compoundolder patientInternal medicinehospital settingmedicinePharmacology (medical)LS4_4Medical prescriptionprescribing patternappropriateness of prescriptions chronic kidney disease hospital setting older patients prescribing patterns real-world data.Original ResearchPharmacologyCreatininereal-world databusiness.industryRetrospective cohort studymedicine.diseaseolder patientsreal-world data.appropriateness of prescriptions; chronic kidney disease; hospital setting; older patients; prescribing patterns; real-world dataappropriateness of prescriptionschemistryObservational studyTherapeutics. Pharmacologybusinesschronic kidney diseaseKidney diseaseFrontiers in Pharmacology
researchProduct